Evolution of antibody immunity following Omicron BA.1 breakthrough infection
Kaku, C. I.; Starr, T. N.; Zhou, P.; Dugan, H. L.; Khalife, P.; Song, G.; Champney, E. R.; Mielcarz, D. W.; Geoghegan, J. C.; Burton, D. R.; Andrabi, R.; Bloom, J. D.; Walker, L. M.
Show abstract
Understanding the evolution of antibody immunity following heterologous SAR-CoV-2 breakthrough infection will inform the development of next-generation vaccines. Here, we tracked SARS-CoV-2 receptor binding domain (RBD)-specific antibody responses up to six months following Omicron BA.1 breakthrough infection in mRNA-vaccinated individuals. Cross-reactive serum neutralizing antibody and memory B cell (MBC) responses declined by two- to four-fold through the study period. Breakthrough infection elicited minimal de novo Omicron-specific B cell responses but drove affinity maturation of pre-existing cross-reactive MBCs toward BA.1. Public clones dominated the neutralizing antibody response at both early and late time points, and their escape mutation profiles predicted newly emergent Omicron sublineages. The results demonstrate that heterologous SARS-CoV-2 variant exposure drives the evolution of B cell memory and suggest that convergent neutralizing antibody responses continue to shape viral evolution.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination 98%
- Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 96%
- Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma 96%
Similar papers in this journal
- Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants 98%
- Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease 97%
- Dynamics of immune recall following SARS-CoV-2 vaccination or breakthrough infection 96%
Similar papers in this journal
- Mucosal immunity against SARS-CoV-2 variants of concern including Omicron following vaccination 97%
- High-affinity, neutralizing antibodies to SARS-CoV-2 can be made in the absence of T follicular helper cells 97%
- CD4-binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals 96%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.